Popular Articles

Phase 3 Trial Initiated To Evaluate Combination Therapy Of Nexavar(R) And Tarceva(R) In Patients With Liver Cancer
Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
generic viagra online
Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
News of the day
Purdue-developed Tool Can Get Most Pollution Control For The Money
There may be thousands of things large and small that can be done to better control pollution on even the smallest waterways, and a new tool developed at Purdue University may help sort out how to choose the best ones.
Mental Health

Lawmakers Look For New Taxes, Cuts To Pay Reform Bill

Lawmakers are considering deductions on medical expenses, value-added taxes, spending cuts and other options to foot the reform bill. Taxpayers can now claim deductions on medical expenses that exceed 7.5 percent of their incomes, a threshold Finance Committee senators are considering raising to 10 percent in an effort to scrape up about $20 billion to help pay for health reform, the Wall Street Journal reports. The change "would fall hardest on middle-income taxpayers who are uninsured and who come up against expensive health problems." It is less likely medical and dental services purchased by wealthy taxpayers will exceed 7.5 percent of their income, and the value of the deduction is already low for people with lower incomes. "Most likely to be affected by a change to the deduction are households with income between $50,000 and $200,000," the journal reports. The proposal "would be just one part of a broad plan to help pay for a health-care overhaul totaling at least $1 trillion" (Vaughan, 6/22). Other components of potential plans to raise $1 trillion include new taxes, such as a value-added tax on consumption (VAT), "sin taxes" such as those on alcohol, requirements for employers to foot more of their employees health costs, reduced subsidies for low-income people to buy insurance, and hefty cuts to Medicare and other government health programs, Kaiser Health News reports (Gold, Pianin and Appleby, 6/22). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):